KFDA Approves Phase III Clinical Trial for Aropotin

Published: 2005-04-08 06:57:00

Updated: 2005-04-08 06:57:00

TS Corporation announced on April 6th that the Korea Food and Drug Administration (KFDA) has approved the phase III clinical trial for Aropotin, an independently developed, bioengineered treatment for the anemia associated with chronic renal failure in patients with reduced kidney function or on ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK